ASH 2017 | ABVD vs. escBEACOPP in HL: a 10-year study
George Follows
• 9 Dec 2017
In the UK, escalated BEACOPP (escBEACOPP) was introduced as an alternative to ABVD for the treatment of advanced-stage Hodgkin lymphoma (HL). Here, George Follows, BMBCh, PhD, FRCP, FRCPath, of Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK, discusses the 10-year retrospective study of ABVD vs. escBEACOPP in HL patients in both trial (RATHL; Trial: RATHL, NCT00678327) and non-trial settings. Dr Follows expresses excitement at presenting the data at this year’s American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
